Key result
Transcatheter edge-to-edge repair using the Dragonfly-M device was feasible and safe for severe mitral regurgitation, with 100% of patients achieving residual MR ≤2+ at discharge.
Why the study?
Transcatheter mitral valve intervention is a promising alternative therapy for patients with severe MR, prompting evaluation of TEER using a novel device.
Is transcatheter edge-to-edge repair (TEER) using a novel device safe and effective for treating severe mitral regurgitation in patients at high or prohibitive surgical risk?
Comparison
TEER using a novel device
Design
Multicenter, prospective, first-in-human study
Follow-up
30-day
Authors
Loading...
Supports early evaluation of Dragonfly-M TEER; leaves open durability, outcomes, and comparative efficacy versus approved devices.
Is transcatheter edge-to-edge repair (TEER) using a novel device safe and effective for treating severe mitral regurgitation in patients at high or prohibitive surgical risk?
A novel transcatheter edge-to-edge repair (TEER) device demonstrated early safety and feasibility in high-risk patients with severe mitral regurgitation, effectively reducing MR and improving left ventricular dimensions at 30 days.
Liu et al. (2022) studied Severe mitral regurgitation (n=23). Transcatheter edge-to-edge repair (TEER) using the Dragonfly-M device was evaluated on Safety and efficacy (residual MR ≤2+ at discharge). Transcatheter edge-to-edge repair using the Dragonfly-M device was feasible and safe for severe mitral regurgitation, with 100% of patients achieving residual MR ≤2+ at discharge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: